台股 » 個股 » 智擎 » 籌碼相關 » 券商分點績效 » 券商分點個股進出

智擎

(4162)
可現股當沖
  • 股價
    96.1
  • 漲跌
    ▲0.9
  • 漲幅
    +0.95%
  • 成交量
    522
  • 產業
    上櫃 生技醫療類股
  • 306人加入追蹤

    立即追蹤

  • 本地時間:14:30(已收盤)

     
智擎 (4162)籌碼相關-群益金鼎-新店 券商分點個股進出
券商分點績效/獲利分析

透過統計各券商分點在長期買賣某個股的操作績效,來找出真正獲利的贏家所在券商分點,進而追蹤此贏家所操作的股票與軌跡。

群益金鼎-新店 券商分點個股進出

日期買進張數買進均價賣出張數賣出均價收盤價買賣超60日均量成交佔比 大量交易提示
2025/01/20293.3000.0093.6021,2790.16%
2025/01/1500.001194.0593.10-111,380-0.80%
2025/01/0900.002095.9094.60-201,341-1.49%
2025/01/082101.7500.00103.0021,2990.15%
2025/01/0300.00295.5098.30-21,240-0.16%
2024/12/2600.00293.3092.50-21,225-0.16%
2024/12/18187.9000.0088.8011,2200.08%
2024/12/17286.4000.0086.7021,2230.16%
2024/12/16188.7000.0086.3011,2160.08%
2024/12/13688.6700.0088.8061,2090.50%
2024/12/12290.7000.0090.2021,1990.17%
2024/12/06494.2500.0093.3041,1800.34%
2024/12/05494.7500.0094.6041,1700.34%
2024/11/29197.80197.7097.5001,1360.00%
2024/11/28494.50193.3092.4031,1100.27%
2024/11/27196.7000.0094.1011,0950.09%
2024/11/252093.8000.0093.80201,0791.85%
2024/11/2100.00196.4096.20-11,021-0.10%
2024/11/20197.9000.0096.5011,0180.10%
2024/11/19396.2000.0096.0031,0150.30%
2024/11/151100.0000.0099.9019890.10%
2024/11/141106.501105.00101.5009710.00%
2024/11/131107.001106.00106.5009460.00%
2024/11/1200.002104.00104.00-2916-0.22%
2024/11/082102.5000.00103.0028730.23%
2024/11/0700.001101.50103.50-1852-0.12%
2024/11/062105.251103.00102.5018260.12%
2024/11/016106.7566107.92105.00-60730-8.21%
2024/10/2911100.641101.00100.50106041.65%
2024/10/2849100.9900.00102.00495768.49%
2024/10/0900.00191.5089.50-1508-0.20%
2024/08/2300.00186.5085.90-1740-0.14%
2024/08/22287.0000.0086.6027400.27%
2024/08/1300.00184.5084.40-1772-0.13%
2024/08/12185.0000.0084.9017800.13%
2024/08/05084.1000.0083.0007640.00%
2024/08/02091.7000.0092.2007410.00%
2024/07/3000.00393.1793.60-3736-0.41%
2024/07/29395.03494.9094.50-1736-0.14%
2024/07/2600.00294.5097.60-2729-0.27%
2024/07/23294.15193.9094.5017200.14%
2024/07/22192.003.392.4192.00-2.3718-0.32%
2024/07/193.395.06697.9094.20-2.7708-0.38%
2024/07/1800.00499.6599.40-4676-0.59%
2024/07/17297.60298.8098.2006580.00%
2024/07/16697.2000.0097.0066580.91%
2024/07/1500.00998.2898.40-9663-1.36%
2024/07/1200.00296.8095.60-2648-0.31%
2024/07/111095.7000.0095.20106501.54%
2024/07/10296.6000.0096.6026580.30%
2024/07/084100.507100.50100.50-3655-0.46%
2024/07/0500.00497.5097.50-4625-0.64%
2024/07/04696.00896.0096.00-2626-0.32%
2024/07/03597.0000.0096.7056280.80%
2024/07/02198.4000.0097.8016230.16%
2024/07/011097.7600.00101.00106101.64%
2024/06/2800.00497.3597.50-4581-0.69%
2024/06/2600.00495.9597.60-4576-0.69%
2024/06/21294.2000.0093.7026070.33%
2024/06/19294.6000.0093.8026370.31%
2024/06/1800.00296.3095.40-2633-0.32%
2024/06/1300.00396.2096.90-3651-0.46%
2024/06/1200.000.494.3294.80-0.4638-0.07%
2024/06/0700.00693.6094.50-6644-0.93%
2024/06/05390.70490.9092.90-1632-0.16%
2024/05/31191.0000.0090.6017290.14%
2024/05/24393.0000.0092.8038080.37%
2024/05/21395.5000.0095.1038500.35%
2024/05/1700.00498.2597.90-4872-0.46%
2024/05/1500.00694.9093.90-6952-0.63%
2024/05/06293.50294.6093.4001,1750.00%
2024/04/30293.7000.0093.7021,4250.14%
2024/04/26291.4000.0091.5021,4340.14%
2024/04/25290.6000.0090.6021,4490.14%
2024/04/15495.0000.0094.1041,5650.26%
2024/04/1000.00499.3098.80-41,642-0.24%
2024/04/09498.2500.0097.6041,7220.23%
2024/04/03197.60299.2099.00-11,777-0.06%
2024/04/0200.00199.7098.90-11,780-0.06%
2024/04/011100.5000.0099.6011,8050.06%
2024/03/29198.6000.0099.2011,8130.06%
2024/03/2800.001101.0099.40-11,839-0.05%
2024/03/2700.004100.0599.70-41,828-0.22%
2024/03/26498.3500.0096.8041,8180.22%
2024/03/2500.006100.23101.00-61,816-0.33%
2024/03/18093.3000.0093.3001,8550.00%
2024/03/1300.00193.7092.40-11,896-0.05%
2024/03/07396.9000.0099.3031,9300.16%
2024/03/06498.8000.0098.1041,9370.21%
2024/02/2600.001104.00104.50-11,990-0.05%
2024/02/194101.7500.00101.5042,0750.19%
2024/02/162102.001.1102.55102.0012,0960.05%
2024/02/151.1111.985109.50110.50-42,060-0.19%
2024/02/055105.0000.00106.5052,0240.25%
2024/01/3100.003106.00106.00-32,396-0.13%
智擎明、後年新藥將有斬獲 歐洲藥證+一期臨床數據結果Anue鉅亨-2023/11/03
智擎 相關文章